Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- (-) Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- (-) Evidence for Decision Making
- Formulary/Benefit Design
- Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- Value Assessment
- (-) Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Display Only
Showing 73 Results
AMCP Partnership Forum: Preparing for and Managing Rare Diseases
Stakeholders met virtually for an AMCP Partnership Forum to discuss viable solutions to challenges facing people living with rare disorders, such as affordable and timely access to therapies,…
NPC Patient-Reported Measures Research Featured at AMCP Nexus 2020
A panel at the Academy of Managed Care Pharmacy Nexus 2020 explored the tension between patient-reported measures funding and innovation and highlighted published research by NPC and Discern Health.
Multi-Criteria Decision Analysis: A Way to Put Patient Concerns Front and Center in Value Assessment?
NHC and NPC released a white paper outlining multi-criteria decision analysis (MCDA), an approach to value assessment that may more holistically address patients’ concerns, experiences and treatment…
Will the Pandemic Provide the Push for Positive Change?
NPC President and CEO Dan Leonard considers the COVID-19 pandemic and its impact on our health care system, as well as whether we’ll see continued innovation in how we access, administer and pay for…
Valuing Innovation in the Current and Post-Pandemic World
Biopharmaceutical industry experts gathered for a panel discussion at the eyeforpharma Virtual Conference to explore how the value of innovation, productivity and preparedness might change as a…
New National Alliance Report Encourages Inclusion of Employer-Relevant Elements in Value Assessment
The National Alliance of Healthcare Purchaser Coalitions' report evaluated existing value frameworks and offers insights on the relationship between value assessment tools and the employer…
A Conversation About Cystic Fibrosis, Caregiving and Innovation
Lisa Yourman, the mother of two adult children living with cystic fibrosis and the Coalition Chair for Action CF, discusses how advances in medicine and technology are making a difference for her…
QALY Remains a Challenge, Societal Perspective Presents an Opportunity With ICER’s 2020 Value Assessment Framework
NPC evaluates the extent to which ICER's 2020-2023 value assessment framework addresses needed changes.
AMCP Partnership Forum: Optimizing Prior Authorization for Appropriate Medication Selection
Stakeholders focused on the challenges of current prior authorization and step therapy programs, approaches to improve these processes for patient care, and reviewed current legislative activities…
Women Matter in Value Assessments
Sarah Wells Kocsis explains why the Society for Women's Health Research is calling on the Institute for Clinical and Economic Review to ensure its value frameworks and assessments “reflect factors…
NPC Submits Comments on Cures 2.0
The National Pharmaceutical Council (NPC) submitted comments in response to a public request for input on Cures 2.0, an “effort to modernize coverage and access to life-saving cures in the United…
Value Assessments Should Encompass More Than Just Medicines
NPC submitted comments to the Institute for Clinical and Economic Review in response to its request for non-drug assessment topics, noting that value assessments should encompass more than just…
Concerns Raised About ICER’s Adapted Value Assessment Methods for High-Impact ‘Single and Short-term Therapies’
NPC outlines concerns with ICER's final adaptations to its value assessment framework for use when reviewing curative therapies.
NPC Analysis Compares, Contrasts 7 U.S. Value Assessment Frameworks
The National Pharmaceutical Council (NPC) today released an analysis of seven U.S. value assessment frameworks, comparing and contrasting the strengths and limitations associated with each framework…
Are Value Assessment Frameworks Ready for Prime Time?
An analysis from NPC, published in Value in Health, examined efforts from three organizations actively conducting value assessments.
NPC in AJMC: Why We Need Multiple Measures of Cost-Effectiveness in the US
In an editorial for The American Journal of Managed Care, NPC Chief Science Officer and Executive Vice President Dr. Robert Dubois explores the pitfalls of assigning only one organization the…
Rethinking Our Approach to Value Assessment to Ensure the Patient Voice is Heard
According to a panel at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Summit 2018 and summarized this week in Value in Health, even though value assessment frameworks…
NPC Outlines Ways to Make ICER’s Value Assessment Framework More Patient-Centered
NPC submitted comments to the Institute for Clinical and Economic Review (ICER) on ways to improve its value assessment framework and ensure that patient concerns are better addressed in treatment…
NPC in Specialty Pharmacy Times: Why We Need to Consider the Proven Value of Drug Therapies
In his latest column for Specialty Pharmacy Times, National Pharmaceutical Council (NPC) President and Chief Executive Officer Dan Leonard explores recent research from the NPC and RTI Health…
NPC in Specialty Pharmacy Times: International Drug Pricing Index Model Could Restrict Innovation, Access
NPC President and CEO Dan Leonard says that CMS's proposal to tie American drug prices to an international pricing index undermines efforts to prioritize value and improve patient outcomes over…